HealthQuill Neurogenerative Diseases
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More